Hanmi Pharm jumps into an approx. KRW 140 billion market of chronic hepatitis B treaments

Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kwon) will jump into the market of chronic hepatitis B treatments containing tenofovir, which forms a market of approximately KRW 140 billion a year.

After acquiring commercialization approval of ‘Tefovir Tab,’ a hepatitis B treatment, from the Ministry of Food and Drug Safety on the last 11^th, Hanmi Pharm announced to secure an exclusive sales right by ...